日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

EpCAM-PSMA: Potential predictors of treatment outcomes for PSMA-targeted alpha therapies in metastatic castration-resistant prostate cancer

EpCAM-PSMA:转移性去势抵抗性前列腺癌中PSMA靶向α疗法治疗结果的潜在预测因子

Gábor Bakos,Ulrike Bauder-Wüst,Jonathan Landry,Mareike Roscher,Beáta Ramasz,Frank Bruchertseifer,Alfred Morgenstern,Clemens Kratochwil,Vladimír Beneš,Martina Benešová-Schäfer

The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy

个性化骨髓瘤治疗之路:针对患者特异性的单域抗体用于抗独特型放射性核素治疗

Janik Puttemans, Benoit Stijlemans, Marleen Keyaerts, Sam Vander Meeren, Wim Renmans, Karel Fostier, Pieterjan Debie, Heleen Hanssens, Magdalena Rodak, Marek Pruszynski, Kim De Veirman, Karin Vanderkerken, Tony Lahoutte, Alfred Morgenstern, Frank Bruchertseifer, Nick Devoogdt #, Matthias D'Huyvetter

Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer

225Ac 标记单域抗体治疗 HER2pos 癌症的临床前评估

Magdalena Rodak #, Yana Dekempeneer #, Maria Wojewódzka, Vicky Caveliers, Peter Covens, Brian W Miller, Matthijs B Sevenois, Frank Bruchertseifer, Alfred Morgenstern, Tony Lahoutte, Matthias D'Huyvetter #, Marek Pruszyński #

Dose escalation study of targeted alpha therapy with [225Ac]Ac-DOTA-substance P in recurrence glioblastoma - safety and efficacy

[225Ac]Ac-DOTA-P 物质针对复发性胶质母细胞瘤的靶向 α 疗法的剂量递增研究 - 安全性和有效性

Leszek Królicki, Frank Bruchertseifer, Jolanta Kunikowska, Henryk Koziara, Dariusz Pawlak, Radosław Kuliński, Rafał Rola, Adrian Merlo, Alfred Morgenstern

CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma

用锕-225 标记的 CS1 特异性单域抗体可延长多发性骨髓瘤患者的生存期并增加 CD8+ T 细胞和 PD-L1 表达

Kim De Veirman, Janik Puttemans, Ahmet Krasniqi, Thomas Ertveldt, Heleen Hanssens, Ema Romao, Dirk Hose, Cleo Goyvaert, Philip Vlummens, Serge Muyldermans, Karine Breckpot, Frank Bruchertseifer, Alfred Morgenstern, Matthias D'Huyvetter, Nick Devoogdt

First-Generation Bispidine Chelators for 213 BiIII Radiopharmaceutical Applications

用于 213 BiIII 放射性药物应用的第一代双哌啶螯合剂

Frank Bruchertseifer, Peter Comba, Bodo Martin, Alfred Morgenstern, Johannes Notni, Miriam Starke, Hubert Wadepohl

Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing "the lead" into PSMA-targeted alpha therapy?

203Pb/212Pb 标记 PSMA 配体的开发和剂量测定:为 PSMA 靶向 α 疗法带来“领先”?

José Carlos Dos Santos, Martin Schäfer, Ulrike Bauder-Wüst, Wencke Lehnert, Karin Leotta, Alfred Morgenstern, Klaus Kopka, Uwe Haberkorn, Walter Mier, Clemens Kratochwil

Functionalized TiO2 nanoparticles labelled with 225Ac for targeted alpha radionuclide therapy

用 225Ac 标记的功能化 TiO2 纳米粒子用于靶向 α 放射性核素治疗

Edyta Cędrowska, Marek Pruszynski, Agnieszka Majkowska-Pilip, Sylwia Męczyńska-Wielgosz, Frank Bruchertseifer, Alfred Morgenstern, Aleksander Bilewicz

α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts

α 和 β 发射放射性核素对表达癌胚抗原的人类结肠癌异种移植瘤的预定位放射免疫治疗

Sandra Heskamp, Reinier Hernandez, Janneke D M Molkenboer-Kuenen, Markus Essler, Frank Bruchertseifer, Alfred Morgenstern, Erik J Steenbergen, Weibo Cai, Christof Seidl, William J McBride, David M Goldenberg, Otto C Boerman

Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model

免疫活性转基因乳腺癌模型中 α 发射体标记抗 PD-L1 抗体的药代动力学、微尺度分布和剂量测定

Jessie R Nedrow, Anders Josefsson, Sunju Park, Tom Bäck, Robert F Hobbs, Cory Brayton, Frank Bruchertseifer, Alfred Morgenstern, George Sgouros